Finanzas de Iovance Biotherapeutics Inc (IOVA)IOVAIovance Biotherapeutics Inc

Evaluating the bottom line, Iovance Biotherapeutics Inc maintains a gross margin of 46.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -52.26%, while the net margin is -47.64%. These profitability ratios, combined with a Return on Equity (ROE) of -40.36%, provide a clear picture of how effectively IOVA converts its operational activities into shareholder value.

In the context of the broader market, IOVA competes directly with industry leaders such as IMVT and KOD. With a market capitalization of $6.44B, it holds a leading position in the sector. When comparing efficiency, IOVA's gross margin of 46.54% stands against IMVT's N/A and KOD's N/A. Such benchmarking helps identify whether Iovance Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has demonstrated strong revenue growth, with Q2 2026 revenue reported at $99.31 million, and a gross margin improvement to 46.54%. Despite ongoing net losses, the trend in revenue and gross margin is positive, suggesting potential for future profitability.